Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

PATIENTS TAKING TYVASO WALKED FARTHER

The 6-minute walk test

PH-ILD can make it difficult for you to walk more than a short distance. The 6-minute walk test (6MWT) can give you a good clue about how much your lung disease could be impacting your ability to stay active. It measures how far you can walk in 6 minutes.

 

 

TYVASO has been shown to help patients with PH-ILD be more active

In a 16-week PH-ILD clinical study, 6MWTs were compared for people who took TYVASO and those who took a placebo (an inhaled solution without medicine in it).

6mwt results from 16 week PH-ILD clinical study6mwt results from 16 week PH-ILD clinical study
In addition to being able to walk farther, patients taking TYVASO also had less strain on their heart.

NOW APPROVED—TYVASO DPI FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

bubbles pattern